Companies / Uganda
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Uganda Opens ARVs, ACTs Facility
July 2006 | Product LaunchSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Private sector company Quality Chemicals has opened a US$50mn facility in Kampala, Uganda, manufacturing anti-retorviral drugs (ARVs) and artemisinin combiantion therapies (ACTs) for HIV/AIDS and malaria. The GLP and GMP-certifiable plant - a joint venture with Indian generics producer Cipla - is expected to begin full-scale operations in February 2007. Observers have remarked that the project is a significant coup for Uganda, which has been hailed for its efforts to slow the spread of AIDS. Investors had originally considered setting up the plant in South Africa or